Top Markets
Coin of the day
Biora Therapeutics, Inc. Biora Therapeutics, Inc.

Biora Therapeutics, Inc.

PROG
株式のランク #27723
Biora Therapeutics, Inc., a biotechnology firm, focuses on the development and... Biora Therapeutics, Inc., a biotechnology firm, focuses on the development and commercialization of molecular diagnostic products within the United States. Its research and development efforts include targeted oral delivery systems for biotherapeutics, such as PGN-600, an oral liquid formulation of tofacitinib for ulcerative colitis, and PGN-001, an orally administered variant of adalimumab also targeting ulcerative colitis. Beyond this, the company is advancing systemic oral biotherapeutic delivery, exemplified by PGN-OB, which combines an adalimumab variant with their Oral Biotherapeutics Delivery System (OBDS) for inflammatory conditions, and PGN-OB2, pairing a GLP-1 receptor agonist with the OBDS for Type 2 diabetes. Biora Therapeutics also creates innovative diagnostic tools, including the Recoverable Sampling System – an ingestible smart capsule engineered to autonomously locate, collect, and preserve samples from the GI tract for analysis – and PIL Dx, another ingestible smart capsule designed to sample, measure, and transmit data wirelessly. A collaboration with Ionis Pharmaceuticals is underway to assess the OBDS platform for delivering antisense oligonucleotides. Founded in 2010 as Ascendant MDX, Inc., the company adopted the name Progenity, Inc. in November 2013, prior to becoming Biora Therapeutics, Inc. Its headquarters are located in San Diego, California.
株価
$0.8845
最終同期: 2022-05-06
時価総額
$31.01M
変化(1日)
-3.47%
変化(1年)
0.00%
US
取引 Biora Therapeutics, Inc. (PROG)

カテゴリー

Biora Therapeutics, Inc.(PROG)の配当履歴
Biora Therapeutics, Inc.(証券コード:PROG)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのBiora Therapeutics, Inc.(PROG)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴
企業 配当支払い回数
0.00%
US
0.00%
US
0.00%
NL
64.00%
AU
0.00%
CH